These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 16603803

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
    Kovács A, Gyönös I, Magyar J, Bányász T, Nánási PP, Spedding M, Szénási G.
    J Cardiovasc Pharmacol; 2001 Jan; 37(1):78-88. PubMed ID: 11152377
    [Abstract] [Full Text] [Related]

  • 3. Beta-adrenoceptor activation plays a role in the reverse rate-dependency of effective refractory period lengthening by dofetilide in the guinea-pig atrium, in vitro.
    Kovács A, Magyar J, Bányász T, Nánási PP, Szénási G.
    Br J Pharmacol; 2003 Aug; 139(8):1555-63. PubMed ID: 12922944
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
    Cha Y, Wales A, Wolf P, Shahrokni S, Sawhney N, Feld GK.
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia induced electromechanical changes.
    Yang T, Tande PM, Lathrop DA, Refsum H.
    Cardiovasc Res; 1992 Nov; 26(11):1109-15. PubMed ID: 1291089
    [Abstract] [Full Text] [Related]

  • 12. Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol.
    Martin CL, Palomo MA, Mcmahon EG.
    J Pharmacol Exp Ther; 1996 Jul; 278(1):154-62. PubMed ID: 8764346
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents.
    Lynch JJ, Baskin EP, Nutt EM, Guinosso PJ, Hamill T, Salata JJ, Woods CM.
    J Cardiovasc Pharmacol; 1995 Feb; 25(2):336-40. PubMed ID: 7752661
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated guinea pig papillary muscle.
    Pankucsi C, Bányász T, Magyar J, Gyönös I, Kovács A, Szénási G, Varró A, Nánási PP.
    Gen Pharmacol; 1997 Aug; 29(2):275-80. PubMed ID: 9251913
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
    Hashimoto N, Yamashita T, Tsuruzoe N.
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.